RCS - Angle PLC - ANGLE launch of Portrait Flex assay

AngleAnnouncement

04/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD2010La&default-theme=true

RNS Number : 2010L  Angle PLC  04 September 2023

 For immediate release  4 September 2023

 

ANGLE plc ("the Company")

 

LAUNCH OF PORTRAIT FLEX CIRCULATING TUMOR CELL ASSAY

 

The Portrait Flex assay provides tailored analyses performed as a service by
ANGLE's Onc-ADaPT™ laboratories

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumor cell (CTC) diagnostic solutions for the research
and diagnostic oncology market, is pleased to announce the launch of its
Portrait™ Flex CTC assay*. The assay is provided as a service from ANGLE's
Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with
over 10 years' experience in CTC analysis.

 

CTCs captured and harvested using ANGLE's Parsortix(®) technology are
subsequently enumerated and characterised with the Portrait Flex assay.
Samples are analysed using immunofluorescence staining for epithelial,
mesenchymal, blood lineage and nuclear markers, with the opportunity to
include an additional biomarker tailored to customer needs. Examples of
clinically relevant CTC biomarkers that have been researched using Parsortix
technology and published in peer-reviewed publications include HER2, PIK3CA,
PD-L1, EGFR, BRAF, AR-V7 among others.

 

The Portrait Flex assay has an analytical sensitivity** of >93%, and an
analytical specificity** of >95% for both epithelial and mesenchymal
markers. Data from the analysis of clinical samples from 16 metastatic breast
cancer patients identified CTCs in 81% of patients, with 38.5% of the
CTC-positive patients having ≥1 CTC with high HER2 levels highlighting the
capability to assess current HER2 status in breast cancer patients. Of the
patients with CTCs, approximately half showed a mesenchymal only phenotype,
while the others showed a mixed phenotype, highlighting the importance of
Parsortix epitope-independent isolation of CTCs.

 

Combining the use of the Parsortix technology and the Portrait Flex assay
allows for testing that is specific to customer needs and can enhance their
clinical trial evaluations. ANGLE is offering a flexible, full-service
solution to help unlock precision medicine for patients.

 

ANGLE Chief Commercial Officer, Brett Swansiger, commented:

"I am pleased to announce the launch of our new Portrait™ Flex assay in our
Onc-ADaPT™ clinical laboratories, the first of a number of assays that we
will be bringing to market in the coming months for the benefit of our
biopharma customers. This service, provided by a highly experienced team, can
provide valuable data for clinical trials and contribute to the advancement in
personalized cancer care."

 

ANGLE Founder and Chief Executive, Andrew Newland, added:

"To support adoption of its technology by adding "content", ANGLE has been
developing a menu of imaging assays and molecular assays to analyse the CTCs
harvested by the Parsortix system.  These assays support both ANGLE's pharma
services business and product business for third-party customers."

 

*For Research Use Only. Not For Use in Diagnostic Procedures.

 

**Analytical sensitivity = Proportions of spiked cells known to express the
marker(s) of interest which were marker positive in the assay.  Analytical
specificity = Proportions of spiked cells known to NOT express the marker(s)
of interest which were marker negative in the assay.

 

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 Berenberg (NOMAD and Joint Broker)          +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology
market using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumor cell (CTC) harvesting technology known as the Parsortix(®)
system enables complete analysis of the sample including whole cell imaging
and proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFSIAAIVIIV